Abstracts tagged "rheumatoid arthritis"

Abstract Number: 1785 • ACR Convergence 2022
PROs and Sociodemographic Factors in Year Prior to COVID Predict Trajectories of Depressive Symptoms in Adults with RA in First 2 Years of Pandemic: Data from the Canadian Early Arthritis Cohort
Susan Bartlett¹, orit schieir², Marie-France Valois², Janet Pope³, Louis Bessette⁴, Gilles Boire⁵, Carol Hitchon⁶, Edward Keystone⁷, Carter Thorne⁸, Diane Tin⁹, Glen Hazlewood¹⁰ and Vivian Bykerk¹¹, ¹McGill University, Montreal, QC, Canada, ²McGill University, Montréal, QC, Canada, ³University of Western Ontario, London, ON, Canada, ⁴Centre de l'Ostoporose et de Rhumatologie de Québec, Québec, QC, Canada, ⁵Universite de Sherbrooke, Sherbrooke, QC, Canada, ⁶University of Manitoba, Winnipeg, MB, Canada, ⁷Keystone Consulting Enterprises Inc., Toronto, ON, Canada, ⁸Southlake Regional Health Centre, Newmarket, ON, Canada, ⁹The Arthritis Program Research Group, Newmarket, ON, Canada, ¹⁰University of Calgary, Calgary, AB, Canada, ¹¹Hospital for Special Surgery, New York, NY
Background/Purpose: Growing evidence points to considerable mental health impacts of the prolonged COVID-19 pandemic, though data from longitudinal studies in rheumatic diseases are sparse. We…
Abstract Number: 1962 • ACR Convergence 2022
Idiopathic Pulmonary Fibrosis Molecular Profile Correlates with Stage of Rheumatoid Arthritis-Associated Interstitial Lung Disease
Daniel Kass¹, Mehdi Nouraie¹, Yingze Zhang¹, Bryant England², Ted Mikuls³, Gail Kerr⁴, Andreas Reimold⁵, Kevin Gibson¹, Marilyn Glassberg⁶, Paul Dellaripa⁷, Tracy Doyle⁷, Chester Oddis⁸ and Dana Ascherman⁸, ¹University of Pittsburgh School of Medicine, Pittsburgh, PA, ²University of Nebraska Medical Center, Omaha, NE, ³Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE, ⁴Washington DC VAMC/Georgetown and Howard Universities, Washington, DC, ⁵North Texas Veterans Administration Health Care System, Dallas, TX, ⁶Loyola University Chicago Stritch School of Medicine, Chicago, IL, ⁷Brigham and Women's Hospital, Boston, MA, ⁸University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Previous studies have demonstrated clinical, epidemiologic, histopathologic, and genetic overlap between advanced rheumatoid arthritis-associated interstitial lung disease (RA-ILD) and Idiopathic Pulmonary Fibrosis (IPF). Corresponding…
Abstract Number: 1980 • ACR Convergence 2022
Seroconversion After a Third COVID-19 Vaccination in Rheumatoid Arthritis Patients Treated with (ultra-)low Dose Rituximab with a Previous Insufficient Humoral Response Is Associated with Rituximab Dosage
Céleste van der Togt¹, David Ten Cate¹, Janette Rahamat-Langendoen², Bart van den Bemt³, Nathan den Broeder⁴ and Alfons den Broeder⁴, ¹Sint Maartenskliniek, Ubbergen, Netherlands, ²ErasmusMC, Rotterdam, Zuid-Holland, Netherlands, ³Department of Pharmacy, Sint Maartenskliniek, Ubbergen, Netherlands, ⁴Sint Maartenskliniek, Nijmegen, Netherlands
Background/Purpose: Around 60% of rheumatoid arthritis (RA) patients treated with ≥1000 mg rituximab (RTX) has an insufficient deemed humoral response after two COVID-19 vaccinations. Recent…
Abstract Number: 1997 • ACR Convergence 2022
Effects of Short Chain Fatty Acid Supplementation in Modulation of Gut Microbiome and T-Regulatory Cells in Health and New Onset Rheumatoid Arthritis
Rebecca Blank¹, Alba Boix-Amoros², Renuka Nayak³, Anthony Jimenez Hernandez¹, Sydney Catron⁴, Zakwan Uddin⁴, Erin Reilly⁵, Andrew Patterson⁵, Peter Turnbaugh⁶, Jose Clemente² and Jose Scher⁷, ¹NYU School of Medicine, New York, NY, ²Icahn School of Medicine at Mount Sinai, New York, NY, ³University of California San Francisco, San Francisco, CA, ⁴NYU Langone Health, New York, NY, ⁵Pennsylvania State University, College Park, PA, ⁶UCSF, San Francisco, ⁷New York University School of Medicine, New York, NY
Background/Purpose: The gut microbiome and its metabolites are dysregulated in rheumatoid arthritis. Short chain fatty acids (SCFAs), microbial fermentation byproducts of certain gut microbes, induce…
Abstract Number: 2013 • ACR Convergence 2022
Drug Free Remission in Rheumatoid Arthritis: Data from the Randomized Controlled ARCTIC REWIND Trial
Siri Lillegraven¹, Nina Paulshus Sundlisæter¹, Anna-Birgitte Aga¹, Joe Sexton¹, Inge Christoffer Olsen², Hallvard Fremstad³, Cristina Spada⁴, Tor Magne Madland⁵, Christian A. Høili⁶, Gunnstein Bakland⁷, Åse Stavland Lexberg⁸, Inger Johanne Widding Hansen⁹, Inger Myrnes Hansen¹⁰, Hilde Haukeland¹¹, Maud-Kristine Aga Ljoså¹², Ellen Moholt¹, Till Uhlig¹, Daniel Solomon¹³, Désirée van der Heijde¹⁴, Tore K. Kvien¹ and Espen Haavardsholm¹, ¹Diakonhjemmet Hospital, Oslo, Norway, ²Oslo University Hospital, Oslo, Nepal, ³Ålesund Hospital, Helse Møre og Romsdal HF, Ålesund, Norway, ⁴Revmatismesykehuset, Lillehammer, Norway, ⁵Haukeland University Hospital, Bergen, Norway, ⁶Hospital Østfold HF, Moss, Norway, ⁷University Hospital of North-Norway, Tromsø, Norway, ⁸Drammen Hospital, Vestre Viken HF, Drammen, Norway, ⁹Sørlandet Hospital HF, Kristiansand, Norway, ¹⁰Helgelandssykehuset Mo i Rana, Mo i Rana, Norway, ¹¹Martina Hansens Hospital, Bærum, Norway, ¹²Ålesund Hospital. Møre og Romsdal HF, Ålesund, Norway, ¹³Brigham and Women's Hospital, Boston, MA, ¹⁴Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands, Leiden, Netherlands
Background/Purpose: Sustained remission has become an achievable treatment goal for many patients with RA, and drug-free remission has been proposed as a potential extended target…
Abstract Number: 2216 • ACR Convergence 2022
JAK Inhibitors and Risk of Cancer
Amandine Gouverneur¹, Jérôme Avouac², Clément Prati³, Jean-Luc Cracowski⁴, Thierry schaeverbeke⁵, Antoine Pariente¹ and Marie-Elise Truchetet⁵, ¹Université de Bordeaux, Bordeaux, France, ²University of Paris, Paris, France, ³Service de rhumatologie, CHU de Besançon, Besançon, France, ⁴Université de Grenoble, Grenoble, France, ⁵CHU de Bordeaux, Bordeaux, France
Background/Purpose: Recent concerns have been raised about potential increase of cancer risk under JAK inhibitors (JAKi) especially tofacitinib. Discrepant findings have been given by randomized…
Abstract Number: PP15 • ACR Convergence 2022
Coordination of Care by a Healthcare Team for Unexpected and Unusual Side Effects Occurring During a Global Pandemic
Laura Genoves, Arthritis Foundation, Bainbridge Island, WA
Background/Purpose: I am a patient who lives with moderate to severe RA. My quality of life is dependent on medications such as a biologic, DMARDs…
Abstract Number: 0021 • ACR Convergence 2022
DB-2306, a Novel Anti-TNFα Monoclonal Antibody Drug Conjugate, Is a Promising Novel Therapeutic Approach for Autoimmune Disease
Xi Li, Yu Zhang, Bing Li and Haiqing Hua, Duality Biologics, Shanghai, China
Background/Purpose: Small molecule immune modulators, such as glucocorticoids (GCs), are highly effective in treatment for various inflammatory diseases. However, prolonged systemic administration of GCs is…
Abstract Number: 0079 • ACR Convergence 2022
Treatment Persistence in First-Line Biologic and Targeted Synthetic DMARD Users with Dual-Seropositive RA in the Medicare Population
Jeffrey Sparks¹, Hanke Zheng², Taylor Schwartz³, Sang Hee Park², Kris Norris³, Vardhaman Patel⁴, Scott Robinson³, Keith Wittstock⁴, Vadim Khaychuk⁵ and Alison Silverstein³, ¹Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ²Bristol Myers Squibb, Princeton, NJ, ³Inovalon Insights, Bowie, MD, ⁴Bristol Myers Squibb, Lawrence Township, NJ, ⁵Bristol Myers Squibb, Pennington, MA
Background/Purpose: The objective of this study was to compare persistence among first-line (1L) abatacept, TNF inhibitors (TNFi), and Janus kinase inhibitors (JAKi) in patients with…
Abstract Number: 0198 • ACR Convergence 2022
Patient Perspectives on Janus Kinase Inhibitor Use in the Treatment of Inflammatory Arthritis
Savia de Souza¹, Andrew Bassett², Ruth Williams² and Elena Nikiphorou³, ¹Independent, London, United Kingdom, ²King's College London, London, United Kingdom, ³Leiden University Medical Center & King's College London, London, United Kingdom
Background/Purpose: Janus kinase inhibitors (JAKi) have relatively recently been licensed to treat inflammatory arthritis (IA); specifically rheumatoid arthritis (RA) and psoriatic arthritis (PsA). They differ…
Abstract Number: 0250 • ACR Convergence 2022
Performance of Fear Assessment in Inflammatory Rheumatic Diseases (FAIR) Questionnaire in a Cohort of Rheumatoid Arthritis Patients in Argentina
Jose Simon Alcivar-Navarrete¹, Joan Manuel Dapeña¹, Juan Manuel Bande¹, Eliana Rebeca Serrano¹, Maria Alejandra Medina¹, Diana Silvia Klajn¹, Jose Angel Caracciolo¹, Analia Dellepiane², Maria Paula Kohan³, Maria Julia Sosa³, maria de los angeles correa⁴, Maximiliano Machado Escobar⁵, Maria Silvia Yacuzzi⁵, Debora Guaglianone⁶, Mariana Benegas⁷, Emel de Jesus Gonzalez Lobato⁸, Eduardo Kerzberg⁸, Sandra Petruzzeli⁹, Beverly De la Puente Perez¹⁰ and Silvia Beatriz Papasidero¹, ¹Hospital General de Agudos Dr. Enrique Tornu, Buenos Aires, Argentina, ²Centro de Especialidades Medicas Caseros, Casilda, Argentina, ³Hospital Dr. Raul F. Larcade, San Miguel, Buenos Aires, Argentina, ⁴Rheumatology Unit, Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, ⁵Hospital Eva Peron, Banda del Rio Sali, Argentina, ⁶Hospital Provincial de Rosario, Rosario, Santa Fe, Argentina, ⁷Sanatorio Dr. Julio Mendez, Buenos Aires, Argentina, ⁸Hospital General de Agudos Dr. Ramos Mejia, Buenos Aires, Argentina, ⁹Casa Hospital San Juan de Dios, Ramos Mejia, Buenos Aires, Argentina, ¹⁰Hospital General de Agudos Dr. Jose Maria Penna, Buenos Aires, Argentina
Background/Purpose: RA is a systemic disease that can compromise many aspects of patient health. The increased psychological burden of RA is known and multifactorial, recent…
Abstract Number: 0266 • ACR Convergence 2022
Expression of Cytokine and Chemokine Genes in Patients with Clinically Suspect Arthralgia; A Longitudinal Study During Progression to Inflammatory Arthritis or Non-Progression
Judith Heutz¹, Cleo Rogier², Ellis Niemantsverdriet³, Susan van den Eeden⁴, Pascal de Jong⁵, Annemieke Geluk⁶ and Annette van der Helm-van Mil⁷, ¹Erasmus Medical Center, Rotterdam, Netherlands, ²Erasmus MC, Rotterdam, Netherlands, ³LUMC, Leiden, Netherlands, ⁴Leiden University Medical Center (LUMC), Leiden, Netherlands, ⁵ErasmusMC, Hendrik Ido Ambacht, Netherlands, ⁶Leiden University Medical Center (LUMC), Leiden, Zuid-Holland, Netherlands, ⁷Leiden University Medical Center, Erasmus Medical Center, Leiden, Netherlands
Background/Purpose: Autoantibody responses rise years before onset of inflammatory arthritis (IA) and are stable during transitioning from clinically suspect arthralgia (CSA) to IA (1). Cytokine…
Abstract Number: 0284 • ACR Convergence 2022
Compared Mortality and Cardiovascular Safety of JAK Inhibitors and Tocilizumab in Patients with RA : A Systematic Review and Network Meta-analysis
Daniela Chicre¹, Alisson Pugliesi¹, Manoel Barros Bértolo¹, Vani de Abreu Souza Filho¹ and Luiz Sérgio F Carvalho², ¹Universidade Estadual de Campinas, Campinas, São Paulo, Brazil, ²Clarity: Inteligência em Saúde, Brasília, Brazil
Background/Purpose: The ORAL-Surveillance trial showed important data on the comparative safety between Tofacitinib and TNF inhibitors (TNFi) in the treatment of RA, leading to safety…
Abstract Number: 0300 • ACR Convergence 2022
Exposure-Response Analyses of Upadacitinib Effects on Plasma Biomarkers in Rheumatoid Arthritis Patients
Yuli Qian¹, Fang Cai², Thierry Sornasse³, Jie Shen¹, Heidi Camp⁴ and Mohamed-Eslam Mohamed¹, ¹AbbVie, Inc., North Chicago, IL, ²AbbVie, Redwood City, CA, ³AbbVie, South San Francisco, CA, ⁴Abbvie, Winnetka, IL
Background/Purpose: Upadacitinib (UPA) is an oral Janus kinase (JAK) inhibitor approved for the treatment of moderately-to-severely active rheumatoid arthritis (RA). Previous investigations demonstrated UPA modulates…
Abstract Number: 0498 • ACR Convergence 2022
A Longitudinal Assessment of Citrulline-specific CD4 T Cells in CCP+ at Risk Subjects and Patients with New-onset Rheumatoid Arthritis
Jing Song¹, Scott Presnell¹, Cliff Rims², Matthew Dufort¹, Hannah DeBerg¹, Peter Linsley², V. Michael Holers³, Kevin D Deane⁴, Eddie James¹ and Jane Buckner¹, ¹Benaroya Research Institute at Virginia Mason, Seattle, WA, ²Benaroya Research Institute, Seattle, WA, ³University of Colorado, Denver, CO, ⁴University of Colorado Denver Anschutz Medical Campus, Denver, CO
Background/Purpose: Rheumatoid arthritis (RA) is an autoimmune disease, in which autoantibodies targeting citrullinated (cit) peptides can be detected prior to diagnosis. We previously reported an…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].